市場調查報告書

抗肥胖藥的全球市場 - 藥物的各類型、各流通管道、各地區:市場規模、佔有率、未來展望、機會分析

Obesity Management Drugs Market, By Drug Type, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 968752
出版日期 內容資訊 英文 172 Pages
商品交期: 2-3個工作天內
價格
抗肥胖藥的全球市場 - 藥物的各類型、各流通管道、各地區:市場規模、佔有率、未來展望、機會分析 Obesity Management Drugs Market, By Drug Type, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年09月29日內容資訊: 英文 172 Pages
簡介

現在,在世界各國不健康的生活習慣等原因肥胖症的患者增加。對應其動向,抗肥胖藥 (減重藥) 和體重管理技術的需求也有望擴大。

本報告提供全球抗肥胖藥 (肥胖管理藥)的市場相關分析,產品概要,及市場基本結構及促進、阻礙因素,整體市場規模預測 (以金額為準,過去4年、今後8年份),藥物的各類型、各流通管道、各地區的詳細趨勢,主要企業的簡介、業績、策略計劃等調查。

目錄

第1章 分析目的、前提條件

第2章 市場概要

  • 分析概要
    • 市場定義和範圍
  • 摘要整理
  • COM (Coherent Opportunity Map:市場機會藍圖)

第3章 市場力學、規定、趨勢分析

  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會
  • 影響度分析
  • 近幾年主要的動向
  • 法規方案
  • PEST分析
  • 新型冠狀病毒感染疾病 (COVID-19)的影響分析

第4章 全球抗肥胖藥市場:藥物的各類型

  • 簡介
    • 市場佔有率分析
    • 與前一年同期相比成長率 (YoY)的分析
    • 各市場區隔趨勢
  • Bupropion、Naltrexone
    • 簡介
    • 市場規模與其預測,與前一年同期相比成長率 (YoY) (以金額為準)
    • 各市場區隔趨勢
  • Orlistat
  • Lorcaserin
  • Phentermine、Topiramate
  • Liraglutide

第5章 全球抗肥胖藥市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 電子商務

第6章 全球抗肥胖藥市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 法國
    • 西班牙
    • 俄羅斯
    • 其他的歐洲各國
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 東南亞國協
    • 澳洲
    • 韓國
    • 其他的亞太地區各國
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他的南美各國
  • 中東
    • GCC各國
    • 以色列
    • 其他的中東各國
  • 非洲
    • 北部非洲
    • 中部非洲
    • 非洲南部

第7章 競爭情形

  • 企業簡介
    • F Hoffmann La Roche Ltd.
    • GlaxoSmithKline plc.
    • Orexigen Therapeutics, Inc.
    • Arena Pharmaceuticals, Inc.
    • VIVUS, Inc.
    • Novo Nordisk A/S
    • Eisai Co., Ltd.

第8章 附錄

目錄

Title:
Obesity Management Drugs Market, By Drug Type (Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Obesity is defined as excess body fat accumulation. The major factors contributing to obesity throughout the world are diseases and adoption of unhealthy life. Increasing prevalence of obesity in developed and emerging economies of the world is projected to propel the growth of the market during the forecasted period. For instance, according to reports published by the World Federation of Obesity, roughly 27.4 million children in India will be obese by 2030. This rapid increase in childhood obesity in India is expected to increase demand for weight loss and obesity management techniques during the forecast period.

Restraints of the Global Obesity Management Drugs Market

Major factors hampering the growth of the obesity management drugs market during the forecast period constitutes of lack of proper healthcare infrastructure along with improper development and implementation of clinical practice guidelines.

Key features of the study:

  • This report provides in-depth analysis of the global obesity management drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global obesity management drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include F Hoffmann La Roche Ltd., GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., VIVUS, Inc., Novo Nordisk A/S, and Eisai Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global obesity management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Obesity Management Drugs Market, By Drug Type:
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • Global Obesity Management Drugs Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • Global Obesity Management Drugs Market, By Geography:
    • North America
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country:
    • U.S.
    • Canada
    • Europe
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country:
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country:
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East:
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country/Region:
    • Central Africa
    • South Africa
    • North Africa
  • Company Profiles
    • F Hoffmann La Roche Ltd.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
    • GlaxoSmithKline plc.
    • Orexigen Therapeutics, Inc.
    • Arena Pharmaceuticals, Inc.
    • VIVUS, Inc.
    • Novo Nordisk A/S
    • Eisai Co., Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
  • Market Definition and Scope
    • Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis

4. Global Obesity Management Drugs Market, By Drug Type, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Bupropion and Naltrexone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Orlistat
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Lorcaserin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Phentermine and Topiramate
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Liraglutide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends

5. Global Obesity Management Drugs Market, By Distribution Channel, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Hospitals Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • E-commerce
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Obesity Management Drugs Market, By Regions, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

    • Company Profiles
  • F Hoffmann La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Orexigen Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Arena Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • VIVUS, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novo Nordisk A/S
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eisai Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact